{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T01:39:26Z","timestamp":1789695566816,"version":"4.0.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The aberrant aggregation of tau leads to loss of its physiological functions and gain of toxic functions, and plays a crucial role in the pathogenesis of tauopathies including Alzheimer\u2019s disease (AD). Targeting tau aggregation is considered a promising strategy for treating tauopathies. The BRICHOS family consists of a variety of proteins containing the BRICHOS domain. Certain endogenous BRICHOS domains may inhibit the pathological aggregation of disease-associated proteins. However, the effects of the BRICHOS domains on tau aggregation remain unknown. Here we revealed that BRICHOS domains from integral membrane protein 2B (ITM2B), tenomodulin (TNMD), and out at first (OAF) bind to tau and inhibit its aggregation in vitro. Intravenous administration of TNMD BRICHOS alleviates tau aggregation, synaptic dysfunction, and memory deficits in Tau P301S transgenic mice. Thus, TNMD BRICHOS may serve as a potential therapeutic approach for the development of treatments for tauopathies.<\/jats:p>","DOI":"10.1038\/s41419-026-08749-3","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T02:35:02Z","timestamp":1776998102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["TNMD BRICHOS domain attenuates tau pathology and memory deficits in a mouse model of tauopathy"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2948-979X","authenticated-orcid":false,"given":"Dandan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honggui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9116-1296","authenticated-orcid":false,"given":"Guiqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-1472","authenticated-orcid":false,"given":"Zhentao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8749_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-323-98817-9.00015-6","volume":"196","author":"G Devi","year":"2023","unstructured":"Devi G. The tauopathies. Handb Clin Neurol. 2023;196:251\u201365.","journal-title":"Handb Clin Neurol"},{"key":"8749_CR2","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S1474-4422(22)00168-5","volume":"21","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in alzheimer\u2019s disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022;21:726\u201334.","journal-title":"Lancet Neurol"},{"key":"8749_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00702-022-02471-y","volume":"129","author":"F Verde","year":"2022","unstructured":"Verde F. Tau proteins in blood as biomarkers of alzheimer\u2019s disease and other proteinopathies. J Neural Transm. 2022;129:239\u201359.","journal-title":"J Neural Transm"},{"key":"8749_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM. Tau-targeting therapies for alzheimer disease. Nat Rev Neurol. 2018;14:399\u2013415.","journal-title":"Nat Rev Neurol"},{"key":"8749_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE, Ji C, Tetlow AM, Jiang Y, Sigurdsson EM. Tau-targeting therapies for alzheimer disease: current status and future directions. Nat Rev Neurol. 2023;19:715\u201336.","journal-title":"Nat Rev Neurol"},{"key":"8749_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1124\/jpet.120.266122","volume":"374","author":"X Wang","year":"2020","unstructured":"Wang X, Li W, Marcus J, Pearson M, Song L, Smith K, et al. MK-8719, a novel and selective o-GlcNAcase inhibitor that reduces the formation of pathological tau and ameliorates neurodegeneration in a mouse model of tauopathy. J Pharmacol Exp Ther. 2020;374:252\u201363.","journal-title":"J Pharmacol Exp Ther"},{"key":"8749_CR7","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F, Bobbala A, Datta S, Ceniceros R, et al. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate alzheimer disease: lauriet. Neurology. 2023;101:e1391\u2013401.","journal-title":"Neurology"},{"key":"8749_CR8","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J, Ratti E, Rajagovindan R, Viollet L, et al. TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early alzheimer\u2019s disease. Nat Aging. 2023;3:1591\u2013601.","journal-title":"Nat Aging"},{"key":"8749_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.phrs.2015.08.003","volume":"100","author":"LE Guimaraes","year":"2015","unstructured":"Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacolo Res. 2015;100:190\u2013209.","journal-title":"Pharmacolo Res"},{"key":"8749_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl2991","volume":"10","author":"K Hou","year":"2024","unstructured":"Hou K, Pan H, Shahpasand-Kroner H, Hu C, Abskharon R, Seidler P, et al. D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of alzheimer\u2019s disease. Sci Adv. 2024;10:eadl2991.","journal-title":"Sci Adv"},{"key":"8749_CR11","doi-asserted-by":"crossref","unstructured":"Hou K, Ge P, Sawaya MR, Lutter L, Dolinsky JL, Yang Y, et al. How short peptides disassemble tau fibrils in alzheimer\u2019s disease. Nature. 2025;644:1020\u201327.","DOI":"10.1038\/s41586-025-09244-z"},{"key":"8749_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4645","volume":"32","author":"A Leppert","year":"2023","unstructured":"Leppert A, Poska H, Landreh M, Abelein A, Chen G, Johansson J. A new kid in the folding funnel: molecular chaperone activities of the BRICHOS domain. Protein Sci. 2023;32:e4645.","journal-title":"Protein Sci"},{"key":"8749_CR13","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1039\/D2CB00187J","volume":"3","author":"G Chen","year":"2022","unstructured":"Chen G, Andrade-Talavera Y, Zhong X, Hassan S, Biverstal H, Poska H, et al. Abilities of the BRICHOS domain to prevent neurotoxicity and fibril formation are dependent on a highly conserved asp residue. RSC Chem Biol. 2022;3:1342\u201358.","journal-title":"RSC Chem Biol"},{"key":"8749_CR14","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbac087","volume":"2","author":"L Sanchez-Pulido","year":"2022","unstructured":"Sanchez-Pulido L, Ponting CP. OAF: a new member of the BRICHOS family. Bioinform Adv. 2022;2:vbac087.","journal-title":"Bioinform Adv"},{"key":"8749_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/ADR-170051","volume":"2","author":"L Dolfe","year":"2018","unstructured":"Dolfe L, Tambaro S, Tigro H, Del CM, Hoozemans J, Wiehager B, et al. The bri2 and bri3 BRICHOS domains interact differently with abeta(42) and alzheimer amyloid plaques. J Alzheimers Dis Rep. 2018;2:27\u201339.","journal-title":"J Alzheimers Dis Rep"},{"key":"8749_CR16","doi-asserted-by":"publisher","first-page":"E2752","DOI":"10.1073\/pnas.1715951115","volume":"115","author":"ME Oskarsson","year":"2018","unstructured":"Oskarsson ME, Hermansson E, Wang Y, Welsh N, Presto J, Johansson J, et al. BRICHOS domain of bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. Proc Natl Acad Sci USA. 2018;115:E2752\u2013E2761.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8749_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102366","volume":"219","author":"Y Andrade-Talavera","year":"2022","unstructured":"Andrade-Talavera Y, Chen G, Pansieri J, Arroyo-Garcia LE, Toleikis Z, Smirnovas V, et al. S100a9 amyloid growth and s100a9 fibril-induced impairment of gamma oscillations in area CA3 of mouse hippocampus ex vivo is prevented by bri2 BRICHOS. Prog Neurobiol. 2022;219:102366.","journal-title":"Prog Neurobiol"},{"key":"8749_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.812808","volume":"9","author":"DV Oliveira","year":"2022","unstructured":"Oliveira DV, Svensson J, Zhong X, Biverstal H, Chen G, Karlstrom H. Molecular chaperone BRICHOS inhibits CADASIL-mutated NOTCH3 aggregation in vitro. Front Mol Biosci. 2022;9:812808.","journal-title":"Front Mol Biosci"},{"key":"8749_CR19","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.1021\/bi900135c","volume":"48","author":"C Nerelius","year":"2009","unstructured":"Nerelius C, Gustafsson M, Nordling K, Larsson A, Johansson J. Anti-amyloid activity of the c-terminal domain of proSP-c against amyloid beta-peptide and medin. Biochemistry. 2009;48:3778\u201386.","journal-title":"Biochemistry"},{"key":"8749_CR20","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1074\/jbc.RA118.004538","volume":"294","author":"S Tambaro","year":"2019","unstructured":"Tambaro S, Galan-Acosta L, Leppert A, Chen G, Biverstal H, Presto J, et al. Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. J Biol Chem. 2019;294:2606\u201315.","journal-title":"J Biol Chem"},{"key":"8749_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.neuron.2014.04.047","volume":"82","author":"DW Sanders","year":"2014","unstructured":"Sanders DW, Kaufman SK, DeVos SL, Sharma AM, Mirbaha H, Li A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82:1271\u201388.","journal-title":"Neuron"},{"key":"8749_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcdb.2022.05.028","volume":"139","author":"J Griffiths","year":"2023","unstructured":"Griffiths J, Grant S. Synapse pathology in alzheimer\u2019s disease. Semin Cell Dev Biol. 2023;139:13\u201323.","journal-title":"Semin Cell Dev Biol"},{"key":"8749_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-023-00823-1","volume":"23","author":"B Dejanovic","year":"2024","unstructured":"Dejanovic B, Sheng M, Hanson JE. Targeting synapse function and loss for treatment of neurodegenerative diseases. Nat Rev Drug Discov. 2024;23:23\u201342.","journal-title":"Nat Rev Drug Discov"},{"key":"8749_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"J Avila","year":"2004","unstructured":"Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev. 2004;84:361\u201384.","journal-title":"Physiol Rev"},{"key":"8749_CR25","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jalz.2015.12.014","volume":"12","author":"AD Alonso","year":"2016","unstructured":"Alonso AD, Beharry C, Corbo CP, Cohen LS. Molecular mechanism of prion-like tau-induced neurodegeneration. Alzheimers Dement. 2016;12:1090\u20137.","journal-title":"Alzheimers Dement"},{"key":"8749_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3389\/fnins.2018.00267","volume":"12","author":"SL DeVos","year":"2018","unstructured":"DeVos SL, Corjuc BT, Oakley DH, Nobuhara CK, Bannon RN, Chase A, et al. Synaptic tau seeding precedes tau pathology in human Alzheimer\u2019s disease brain. Front Neurosci. 2018;12:267.","journal-title":"Front Neurosci"},{"key":"8749_CR27","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41591-020-0938-9","volume":"26","author":"S Dujardin","year":"2020","unstructured":"Dujardin S, Commins C, Lathuiliere A, Beerepoot P, Fernandes AR, Kamath TV, et al. Tau molecular diversity contributes to clinical heterogeneity in Alzheimer\u2019s disease. Nat Med. 2020;26:1256\u201363.","journal-title":"Nat Med"},{"key":"8749_CR28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","volume":"9","author":"SS Shafiei","year":"2017","unstructured":"Shafiei SS, Guerrero-Munoz MJ, Castillo-Carranza DL. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci. 2017;9:83.","journal-title":"Front Aging Neurosci"},{"key":"8749_CR29","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.neuron.2023.04.020","volume":"111","author":"M Colom-Cadena","year":"2023","unstructured":"Colom-Cadena M, Davies C, Sirisi S, Lee J, Simzer EM, Tzioras M, et al. Synaptic oligomeric tau in alzheimer\u2019s disease - a potential culprit in the spread of tau pathology through the brain. Neuron. 2023;111:2170\u201383.e6.","journal-title":"Neuron"},{"key":"8749_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","volume":"88","author":"CM Wischik","year":"2014","unstructured":"Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for alzheimer\u2019s disease. Biochem Pharmacol. 2014;88:529\u201339.","journal-title":"Biochem Pharmacol"},{"key":"8749_CR31","doi-asserted-by":"crossref","unstructured":"Zadrozny M, Drapich P, Gasiorowska-Bien A, Niewiadomski W, Harrington CR, Wischik CM, et al. Neuroprotection of cholinergic neurons with a tau aggregation inhibitor and rivastigmine in an Alzheimer \u2019s-like tauopathy mouse model. Cells 2024;13:642.","DOI":"10.3390\/cells13070642"},{"key":"8749_CR32","doi-asserted-by":"publisher","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci USA. 1996;93:11213\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8749_CR33","doi-asserted-by":"publisher","first-page":"e52389","DOI":"10.1371\/journal.pone.0052389","volume":"7","author":"M Hosokawa","year":"2012","unstructured":"Hosokawa M, Arai T, Masuda-Suzukake M, Nonaka T, Yamashita M, Akiyama H, et al. Methylene blue reduced abnormal tau accumulation in p301l tau transgenic mice. PLoS ONE. 2012;7:e52389.","journal-title":"PLoS ONE"},{"key":"8749_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejmech.2017.07.070","volume":"139","author":"M Jouanne","year":"2017","unstructured":"Jouanne M, Rault S, Voisin-Chiret AS. Tau protein aggregation in alzheimer\u2019s disease: an attractive target for the development of novel therapeutic agents. Eur J Med Chem. 2017;139:153\u201367.","journal-title":"Eur J Med Chem"},{"key":"8749_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109445","volume":"113","author":"N Karimi","year":"2022","unstructured":"Karimi N, Bayram CF, Arslan E, Saghazadeh A, Rezaei N. Tau immunotherapy in alzheimer\u2019s disease and progressive supranuclear palsy. Int Immunopharmacol. 2022;113:109445.","journal-title":"Int Immunopharmacol"},{"key":"8749_CR36","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388:2873\u201384.","journal-title":"Lancet"},{"key":"8749_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/dvdy.1126","volume":"221","author":"O Brandau","year":"2001","unstructured":"Brandau O, Meindl A, Fassler R, Aszodi A. A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin-I. Dev Dynam. 2001;221:72\u201380.","journal-title":"Dev Dynam"},{"key":"8749_CR38","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/oby.2007.613","volume":"15","author":"A Tolppanen","year":"2007","unstructured":"Tolppanen A, Pulkkinen L, Kolehmainen M, Schwab U, Lindstrom J, Tuomilehto J, et al. Tenomodulin is associated with obesity and diabetes risk: the finnish diabetes prevention study. Obesity. 2007;15:1082\u20138.","journal-title":"Obesity"},{"key":"8749_CR39","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/GIM.0b013e3181772129","volume":"10","author":"A Tolppanen","year":"2008","unstructured":"Tolppanen A, Pulkkinen L, Herder C, Koenig W, Kolehmainen M, Lindstrom J, et al. The genetic variation of the tenomodulin gene (TNMD) is associated with serum levels of systemic immune mediators-the finnish diabetes prevention study. Genet Med. 2008;10:536\u201344.","journal-title":"Genet Med"},{"key":"8749_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1152\/japplphysiol.00198.2012","volume":"113","author":"J Qi","year":"2012","unstructured":"Qi J, Dmochowski JM, Banes AN, Tsuzaki M, Bynum D, Patterson M, et al. Differential expression and cellular localization of novel isoforms of the tendon biomarker tenomodulin. J Appl Physiol. 2012;113:861\u201371.","journal-title":"J Appl Physiol"},{"key":"8749_CR41","doi-asserted-by":"publisher","first-page":"23504","DOI":"10.1021\/jacs.5c01369","volume":"147","author":"C Morman","year":"2025","unstructured":"Morman C, Leppert A, Pizzirusso G, Zheng Z, Sun X, Kumar R, et al. Chaperone-mediated regulation of tau phase separation, fibrillation, and toxicity. J Am Chem Soc. 2025;147:23504\u201318.","journal-title":"J Am Chem Soc"},{"key":"8749_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3233\/JAD-230051","volume":"93","author":"J Rhyu","year":"2023","unstructured":"Rhyu J, Park J, Shin B, Kim Y, Kim E, Kim KW, et al. A novel c.800g>c variant of the ITM2b gene in familial korean dementia. J Alzheimers Dis. 2023;93:403\u20139.","journal-title":"J Alzheimers Dis"},{"key":"8749_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.","journal-title":"Science"},{"key":"8749_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5063","volume":"33","author":"G Chen","year":"2024","unstructured":"Chen G, Wang Y, Zheng Z, Jiang W, Leppert A, Zhong X, et al. Molecular basis for different substrate-binding sites and chaperone functions of the BRICHOS domain. Protein Sci. 2024;33:e5063.","journal-title":"Protein Sci"},{"key":"8749_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ab.2012.03.014","volume":"425","author":"F Sasaki","year":"2012","unstructured":"Sasaki F, Okuno T, Saeki K, Min L, Onohara N, Kato H, et al. A high-affinity monoclonal antibody against the FLAG tag useful for g-protein-coupled receptor study. Anal Biochem. 2012;425:157\u201365.","journal-title":"Anal Biochem"},{"key":"8749_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26584-2","volume":"12","author":"GG Moreira","year":"2021","unstructured":"Moreira GG, Cantrelle FX, Quezada A, Carvalho FS, Cristovao JS, Sengupta U, et al. Dynamic interactions and Ca (2+)-binding modulate the holdase-type chaperone activity of S100 b preventing tau aggregation and seeding. Nat Commun. 2021;12:6292.","journal-title":"Nat Commun"},{"key":"8749_CR47","doi-asserted-by":"crossref","unstructured":"Liu C, Meng L, Gao Y, Chen J, Zhu M, Xiong M, et al. PM2.5 triggers tau aggregation in a mouse model of tauopathy. JCI Insight 2024;9:e176703.","DOI":"10.1172\/jci.insight.176703"},{"key":"8749_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00518-y","volume":"17","author":"G Zhang","year":"2022","unstructured":"Zhang G, Meng L, Wang Z, Peng Q, Chen G, Xiong J, et al. Islet amyloid polypeptide cross-seeds tau and drives the neurofibrillary pathology in alzheimer\u2019s disease. Mol Neurodegener. 2022;17:12.","journal-title":"Mol Neurodegener"},{"key":"8749_CR49","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/nprot.2006.356","volume":"1","author":"S Kaech","year":"2006","unstructured":"Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406\u201315.","journal-title":"Nat Protoc"},{"key":"8749_CR50","doi-asserted-by":"crossref","unstructured":"Bromley-Brits K, Deng Y, Song W. Morris water maze test for learning and memory deficits in alzheimer\u2019s disease model mice. J Vis Exp. 2011;20:2920.","DOI":"10.3791\/2920"},{"key":"8749_CR51","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1093\/bioinformatics\/btw514","volume":"32","author":"LC Xue","year":"2016","unstructured":"Xue LC, Rodrigues JP, Kastritis PL, Bonvin AM, Vangone A. PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. Bioinformatics. 2016;32:3676\u20138.","journal-title":"Bioinformatics"},{"key":"8749_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.07454","volume":"4","author":"A Vangone","year":"2015","unstructured":"Vangone A, Bonvin AM. Contacts-based prediction of binding affinity in protein-protein complexes. eLife. 2015;4:e07454.","journal-title":"eLife"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08749-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:53:22Z","timestamp":1780631602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8749"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08749-3","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Renmin Hospital of Wuhan University, with the IACUC issue number (Renmin Hospital of Wuhan University (WDRM) animal (welfare)) 20250102D. The present study does not include human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"542"}}